Zithromax

Zithromax n in the treatment of lower respiratory tract infections
More than 20 years of experience in the clinical practice of Zithromax (Azithromycin) suggests its truly worldwide recognition. During this time, the drug has proven itself in the treatment of various infectious diseases, especially bronchopulmonary infections.
According to the study of the European Society of Antimicrobial Chemotherapy (ESAC), conducted in 2001-2002. In most European countries, macrolides are the second-largest group of drugs consumed in ambulatory practice, second only after penicillin. Zithromax and clarithromycin are the "top five" most actively traded in the world antimicrobial agents.
Consumption of Zithromax has reached the enormous amount and continues to grow steadily. In 1999, Zithromax was the most prescribed drug of macrolides in the world (IMS Drug Monitor, 1999), and its volume sales in 2002 exceeded 1 billion U.S. dollars.
The basic properties of Azithromycin, allowing to keep a strong position in the treatment of lower respiratory tract infections, are as follows:
  • Low resistance S. pneumoniae and H. influenzae to Azithromycin;
  • High concentration in various bronchopulmonary structures;
  • The existence of post antibiotic effect;
  • The absence of clinically significant interactions with other drugs;
  • Convenient dosing regimen;
  • The presence of the drug in different dosage forms;
  • High activity against major pathogens of lower respiratory tract infections (S. pneumoniae, H. influenzae, M. catarrhalis, S. aureus, Enterobactericae);
  • Activity against intracellular atypical pathogens;
  • Well tolerated and proved safe;